– In 439 patients ≥60 years without adverse‑risk cytogenetics enrolled to NCRI AML18, DAGO2 produced higher post‑course‑1 CR/CRi and MRD‑negative CR rates than CPX‑351.
– Three‑year event‑free survival (EFS) and overall survival (OS) favored DAGO2: 3‑yr EFS 34% vs 27% (HR 0.73, p=0.012) and 3‑yr OS 52% vs 35% (HR 0.62, p=0.001).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
